Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)39.95
  • Today's Change0.50 / 1.27%
  • Shares traded3.55m
  • 1 Year change-1.36%
  • Beta0.6602
Data delayed at least 15 minutes, as of May 16 2024 07:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 09-May-24
Select bar for recommendation details.
Recommendations09-May-24
Buy11
Outperform15
Hold1
Underperform0
Sell0

Share price forecast in CNY

The 24 analysts offering 12 month price targets for Innovent Biologics Inc have a median target of 55.03, with a high estimate of 76.84 and a low estimate of 32.03. The median estimate represents a 39.50% increase from the last price of 39.45.
High94.8%76.84
Med39.5%55.03
Low-18.8%32.03

Earnings history & estimates in CNY

Innovent Biologics Inc reported annual 2023 losses of -0.66 per share on Mar 20, 2024.
Average growth rate-1.65%
More ▼

Revenue history & estimates in CNY

Innovent Biologics, Inc. had revenues for the full year 2023 of 6.21bn. This was 36.21% above the prior year's results.
Average growth rate+80.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.